Broker Briefing Digital Event Featuring Tolga Kumova – BrokerBriefing.Com
About the event
HERE’s WHAT YOU MISSED!
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam
HIGHLIGHTS VIDEO
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam
COMPANIES PRESENTING
Paradigm Biopharmaceuticals Lttd (ASX:PAR)
Paradigm Biopharmaceuticals Limited (ASX:PAR) listed on the ASX in August 2015 and is focused on repurposing pentosan polysulfate sodium (PPS), a drug known for its anit-inflammatory and anti-thrombotic properties. for new orthopaedic and rare disease applications. The Company addresses conditions that start with and are sustained by inflammation. Lead clinical indications involve treating osteoarthritis (and associated pain and injuries that result in bone marrow edema lesion, BML), rare joint diseases (mucopolysaccharidoses, MPS) and viral arthritis (Ross River and Chikungunya virus). Paradigm’s aim is to develop and commercialise an ethical, safe and effective Pharmaceutical Agent for the treatment of musculoskeletal disorders in humans with degenerative disease driven by injury, aging or genetic predisposition
PharmAust Limited (ASX:PAA)
PharmAust Limited (ASX:PAA) is an Australia-based clinical-stage company that develops targeted cancer therapies for human and animal healthcare. Founded in 2000 and operating in various fields for many years, in 2013 Pitney Pharmaceuticals was reversed into PharmAust to create the current structure focused on two wholly owned subsidiaries (Pitney Pty Ltd and Epichem Ltd). The business operates as a drug discovery and development company and focuses on repurposing marketed drugs. Monepantel (MPL), PharmAust’s leading drug candidate, is a small molecule marketed for the treatment of parasitic infections in sheep (by Elanco). MPL, one of the most promising products in the company’s pipeline, is being investigated in Phase I/II trials. It acts as a modulator of the mTOR pathway that eventually drives the treatment of cancers.
VIEW THE STREAM OF THE EVENT
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam
EVENT CO-HOST & SPONSOR
We are delighted to welcome Pol Roger as our event Co-Host and Sponsor.
Pol Roger has long been the choice of British Royalty and was also Sir Winston Churchill’s favourite beverage. With a rich heritage of excellence spanning over five generations, Pol Roger’s uncompromising reputation for quality is evident in every stunning mouthful.
Please join us at this special event where their champagne’s will be showcased for tasting!
EVENTS GALLERY
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.
